Immediate Impact

4 from Science/Nature 83 standout
Sub-graph 1 of 22

Citing Papers

Neutrophil Membrane‐Camouflaged Polyprodrug Nanomedicine for Inflammation Suppression in Ischemic Stroke Therapy
2024 Standout
Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies
2023 Standout
9 intermediate papers

Works of EW Radue being referenced

Disease control and safety in relapsing remitting multiple sclerosis (RRMS) patients switching from natalizumab to fingolimod: a 32-week, rater- and patient-blind, randomized, parallel-group study (TOFINGO)
2013
Long-Term Efficacy and Safety of Fingolimod (FTY720) in Relapsing-Remitting Multiple Sclerosis (RRMS): Results from the Extension of the Phase III FREEDOMS Study (S41.004)
2012
and 1 more

Author Peers

Author Last Decade Papers Cites
EW Radue 324 157 18 159 14 658
Sherrill Purves 466 74 20 107 13 831
Léorah Freeman 437 198 30 65 36 761
Angela Pisani 394 142 2 71 12 609
Eva Milano 253 114 8 59 15 602
L Metz 398 77 13 121 15 720
Ernst W. Radü 239 66 7 104 18 713
O Lyon-Caen 383 88 12 45 35 814
Rozie Arnaoutelis 540 145 4 62 5 782
David Paling 432 91 11 34 32 706
Seth Bouvier 263 65 47 288 9 771

All Works

Loading papers...

Rankless by CCL
2026